Optomed Q2: Revenue growth, expanding margins

Research Note



Redeye maintains at this point Optomed's valuation at EUR 13 per share after the strong Q2 report. We expect the company to continue delivering solid results this year, followed by stronger growth in 2022, both of camera and of software revenues, and further improving gross margins.


Gergana Almquist

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.